Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway

Rejuvenation Research

Volumn 13, Issue 1, 2010, Pages 55-64

  Yu, Song ^a   Zheng, Wei ^a   Xin, Na ^a   Chi, Zhi Hong ^a   Wang, Nai Qian ^a   Nie, Ying Xue ^a   Feng, Wan Yu ^a   Wang, Zhan You ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDNIUM ION; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CURCUMIN; PYRIDINIUM DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; CASPASE 3; CELL DEATH; CELL LINE; CURCUMIN; DOPAMINE; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; PROTO-ONCOGENE PROTEINS C-JUN; SUBSTANTIA NIGRA;

MUS;

EID: 77949532182     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0908     Document Type: Article

References (45)

1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
2. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1:120-129.
3. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000;407:802-809.
4. Li X, Du Y, Fan X, Yang D, Luo G, Le W. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J Neuropathol Exp Neurol 2008;67:933-944.
5. Wang W, Shi L, Xie Y, Ma C, Li W, Su X, Huang S, Chen R, Zhu Z, Mao Z, Han Y, Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 2004;48:195-202.
6. Pan J, Zhao YX, Wang ZQ, Jin L, Sun ZK, Chen SD. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci Lett 2007;428:82-87.
7. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: A short review. Life Sci 2006;78:2081-2087.
8. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009;11: 241-249. 9.
9. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008;174:27-37.
10. Wakade C, King MD, Laird MD, Alleyne CH, Jr., Dhanda-pani KM. Curcumin attenuates vascular inflammation and cerebral vasospasm after subarachnoid hemorrhage in mice. Antioxid Redox Signal 2009;11:35-45.
11. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008;10:511-545.
12. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frauts-chy SA, Cole GM. Beta-amyloid oligomers induce phos-phorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009;29:9078-9089.
13. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008;44: 907-917.
14. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammo-pharmacol 2008;16:96-99.
15. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-5901.
16. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-8377.
17. Thiyagarajan M, Sharma SS. Neuroprotective effect of cur-cumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 2004;74:969-985.
18. Chen J, Tang XQ, Zhi JL, Cui Y, Yu HM, Tang EH, Sun SN, Feng JQ, Chen PX. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 2006;11: 943-953.
19. Mythri RB, Jagatha B, Pradhan N, Andersen J, Bharath MM. Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? Antioxid Redox Signal 2007;9:399-408.
20. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT. Neuroprotective properties of the natural phenolic an-tioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 2005;39:1119-1125.
21. Fiorillo C, Becatti M, Pensalfini A, Cecchi C, Lanzilao L, Donzelli G, Nassi N, Giannini L, Borchi E, Nassi P. Curcumin protects cardiac cells against ischemia-reperfusion injury: Effects on oxidative stress, NF-kappaB, and JNK pathways. Free Radic Biol Med 2008;45:839-846.
22. Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway. J Neurochem 2006;97:1126-1135.
23. Zhang LH, Wang X, Zheng ZH, Ren H, Stoltenberg M, Danscher G, Huang L, Rong M, Wang ZY. Altered expression and distribution of zinc transporters in APP=PS1 transgenic mouse brain. Neurobiol Aging 2008;31:74-87.
24. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars com-pacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
25. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neuro-toxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine in mice. Science 1984;224:1451-1453.
26. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
27. Borsello T, Forloni G. JNK signalling: A possible target to prevent neurodegeneration. Curr Pharm Des 2007;13:1875-1886.
28. Rawal N, Parish C, Castelo-Branco G, Arenas E. Inhibition of JNK increases survival of transplanted dopamine neurons in Parkinsonian rats. Cell Death Differ 2007;14:381-383.
29. Junn E, Mouradian MM. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem 2001;78:374-383.
30. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, Kalyanaraman B. 1-Methyl-4-phenylpyridinium (MPP\+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 2003;371:151-164.
31. Commandeur JN, Vermeulen NP. Cytotoxicity and cyto-protective activities of natural compounds. The case of cur-cumin. Xenobiotica 1996;26:667-680.
32. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC. Strategy and planning for chemopreventive drug development: Clinical development plans II. J Cell Biochem Suppl 1996;26:54-71.
33. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J Altern Complement Med 2003;9:161-168.
34. Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A, Shimohama S. Estradiol protects dopaminergic neurons in a MPP\+Parkinson's disease model. Neuropharmacology 2002;42:1056-1064.
35. Dong J, Song N, Xie J, Jiang H. Ghrelin antagonized 1-methyl-4- phenylpyridinium (MPP(\+))-induced apoptosis in MES23.5 cells. J Mol Neurosci 2009;37:182-189.
36. Landau AM, Luk KC, Jones ML, Siegrist-Johnstone R, Young YK, Kouassi E, Rymar VV, Dagher A, Sadikot AF, Desbarats J. Defective Fas expression exacerbates neurotox-icity in a model of Parkinson's disease. J Exp Med 2005; 202:575-581.
37. Harper SJ, Saporito MS, Hewson L, Young L, Smith D, Rigby M, Jackson P, Curtis N, Swain C, Hefti F, Vaught JL, Sir-inathsinghji D. CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fim-bria-fornix lesion. Neuroreport 2000;11:2271-2276.
38. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347= KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J Pharmacol Exp Ther 1999;288:421-427.
39. Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000;75:1200-1208.
40. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyr-azolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-13686
41. Srivastava R, Srimal RC. Modification of certain inflammation-induced biochemical changes by curcumin. Indian J Med Res 1985;81:215-223.
42. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001;14:483-489.
43. Kitamura Y, Itano Y, Kubo T, Nomura Y. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL=6 mice. J Neuroimmunol 1994;50:221-224.
44. Matsuura K, Makino H, Ogawa N. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopa-mine content in rats with intrastriatal injection of 6-hydroxydopamine. Exp Neurol 1997;146:526-535.
45. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999;156:50-61.